Deciphera Pharmaceuticals announces US FDA acceptance of NDA and priority review for ripretinib in patients with advanced gastrointestinal stromal tumours

The US FDA’s Center for Drug Evaluation and Research (Credit: The U.S. Food and Drug Administration/Wikipedia.org)